
Nevro (NVRO) Stock Forecast & Price Target
Nevro (NVRO) Analyst Ratings
Bulls say
Nevro Corp has demonstrated strong revenue growth in the latter half of the year, supported by a comprehensive guidance that includes trials, replacements, competitive conversions, and new patients for 2024. The ongoing scaling of its Costa Rica manufacturing facility is expected to enhance gross margins over the long term, while improvements in operational efficiency are poised to further strengthen profitability. The company is actively investing in its R&D pipeline and diversifying its portfolio, which, along with strategic changes to its commercial team, positions Nevro favorably for continued growth and enhanced market penetration.
Bears say
Nevro Corp's outlook is negatively impacted by a sequential revenue decline, as Q4 revenue of $96.9 million represented a 7% year-over-year decrease, coupled with a 15.2% drop in U.S. trial procedures on an annual basis. The company has also revised its full-year 2024 revenue guidance downwards, projecting $400-405 million, reflecting a decline of 5-6% year-over-year. Furthermore, anticipated lower gross margins in Q4 2024, combined with decreased sales volumes, are expected to create ongoing margin pressures into 2025.
This aggregate rating is based on analysts' research of Nevro and is not a guaranteed prediction by Public.com or investment advice.
Nevro (NVRO) Analyst Forecast & Price Prediction
Start investing in Nevro (NVRO)
Order type
Buy in
Order amount
Est. shares
0 shares